Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

1f21bafd-41c5-4cf4-a15f-79dc22e91491 - samples

ABSTRACT: Homologous recombination deficiency (HRD) score in a large cohort of 55 triple-negative breast cancer PDX

PROVIDER: EGAD00001008839 | EGA |

REPOSITORIES: EGA

ACCESS DATA

Json Xml

Similar Datasets

Genomic determination for Homologous Recombination Deficiency (HRD) by shallow Whole Genome Sequencing (sWGS)

Project description:Genomic determination for Homologous Recombination Deficiency (HRD) by shallow Whole Genome Sequencing (sWGS) with shallowHRD (PMID : 32315385) on 55 triple-negative breast cancer Patient Derived-Xenograft (PDX) treated with platinum

| EGAS00001005926 | EGA

18 PDX of triple-negative breast cancer genotyped with SNP6 Affymetrix arrays

Project description:To characterize Homologous recombination deficiency (BRCAness) in triple-negative breast cancer PDX models genomic signature was utilized. After normalization using Genotyping Console we obtained absolute copy number profiles using the GAP software (Popova et al, Genome Biol, 2009). The number of Large-scale State Transitions (LSTs) was used to annotate PDX as BRCAness or not (Popova et al, Cancer Res 2012).

2020-01-01 | E-MTAB-8654 | biostudies-arrayexpress

22 PDX of triple-negative breast cancer genotyped with Affymetrix Cytoscan HD

Project description:To characterize Homologous recombination deficiency (BRCAness) in triple-negative breast cancer PDX models genomic signature was utilized. After normalization using ChAS we obtained absolute copy number profiles using the GAP software (Popova et al, Genome Biol, 2009). The number of Large-scale State Transitions (LSTs) was used to annotate PDX as BRCAness or not (Popova et al, Cancer Res 2012).

2020-01-01 | E-MTAB-8653 | biostudies-arrayexpress

A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors

Project description:HS-10502 is a Poly(ADP-ribose) polymerase 1 (PARP1)-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 in subjects with homologous recombination repair (HRR) gene mutant or homologous recombination deficiency (HRD) positive advanced solid tumors.

| 9330 | ecrin-mdr-crc

The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

Project description:Preclinical data support the investigation of PARP inhibitors in other neoplasms exhibiting homologous recombination deficiency (HRD) as monotherapy as well as in combination with chemotherapy. However，in colorectal cancer (CRC), the role of HRD alterations is mostly unknown. This study aims to explore the the Efficacy and Safety of Fluzoparib combined with Irinotecan in the Second-line treatment of HRD alterations metastatic colorectal cancer.

| 8652 | ecrin-mdr-crc

Epigenomic landscape of homologous recombination deficient (HRD) triple-negative breast cancer (TNBC)

Project description:Epigenomic landscape of homologous recombination deficient (HRD) triple-negative breast cancer (TNBC)

| PRJNA1075433 | ENA

Clinical relevance of BRCA1 promoter methylation testing in ovarian cancer patients.

Project description:Homologous-recombination deficiency (HRD) is closely related to PARPi benefit in ovarian cancer (OC). The capacity of BRCA1 promoter methylation to predict prognosis and HRD status remains unclear. We aimed to correlate BRCA1 promoter methylation levels in patients with high-grade OC to HRD status and clinical behavior to assess its clinical relevance.

2023-04-10 | GSE229315 | GEO

Targeting Cyclin K-CDK12 Synergizes with ATR Inhibition by Limiting RPA Chromatin Loading in Triple-Negative Breast Cancer

Project description:Cyclin K-CDK12 inhibition has emerged as a promising therapeutic strategy to induce homologous recombination deficiency (HRD). However, clinical and genomic studies have not clearly linked CDK12 inactivation to HRD. Here, we demonstrate that cyclin K-CDK12 depletion drives a replication stress (RS)-associated vulnerability through RPA regulation. A DNA damage response-focused CRISPR screen identified DNA replication factors and ATR activators as top sensitizers to cyclin K degradation. Consistently, cyclin K-CDK12 depletion synergized with ATR inhibition in triple-negative breast cancer (TNBC) models. Cyclin K degradation reduces RPA chromatin loading and impairs ATR activation, compromising cellular tolerance to RS and increasing susceptibility to ATR inhibition. We show that CDK12-mediated phosphorylation of CDC5L is required for RPA chromatin loading and mediates resistance to combined cyclin K and ATR depletion. Our findings identify cyclin K-CDK12 as a critical regulator of RPA dynamics and support its inhibition as rational therapy for RS-high tumors, including TNBC.

2026-04-26 | GSE328758 | GEO

Targeting Cyclin K-CDK12 Synergizes with ATR Inhibition by Limiting RPA Chromatin Loading in Triple-Negative Breast Cancer [ChIP-seq]

2026-04-27 | GSE328796 | GEO

DirectHRD enables sensitive scar-based classification of homologous recombination deficiency (HRD)

Project description:DirectHRD enables sensitive scar-based classification of homologous recombination deficiency (HRD)

| PRJNA1154313 | ENA